MAIA Biotechnology, Inc. Form 8-K Summary
Business Context and Reporting Period
MAIA Biotechnology, Inc. (MAIA), an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on March 25, 2024. The filing discloses the entry into a Material Definitive Agreement regarding a private placement of equity securities.
Key Financial Metrics and Transaction Details
The filing details a private placement transaction rather than periodic financial performance metrics. Key transaction figures include:
- Aggregate Purchase Price: Approximately $1.33 million.
- Securities Issued: 578,643 shares of Common Stock and warrants to purchase up to 578,643 additional shares.
- Price Per Share: $2.295.
- Warrant Exercise Price: $2.55 per share.
- Warrant Terms: Exercisable commencing six months after issuance with a five-year term.
The filing text does not provide current revenue, profit, cash flow, margins, or total debt figures.
Material Changes and Use of Proceeds
The primary material change is the capital raise intended to fund specific research and development activities. The Company intends to use the net proceeds to fund the first third of the pivotal accelerated approval Part C of the THIO-101 trial in non-small cell lung cancer (NSCLC). The closing of the Private Placement was expected to occur on March 28, 2024.
Outlook, Risks, and Contingencies
The transaction relies on exemptions from registration under Section 4(a)(2) and/or Rule 506 of the Securities Act of 1933. The securities issued are restricted and do not contain registration rights. The Warrants do not include provisions relating to price protection. The filing incorporates by reference a press release dated March 26, 2024, regarding the pricing of the placement.
Investor Verification Checklist
- Verify the actual closing date of the Private Placement (expected March 28, 2024) and confirmation of fund receipt.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Warrant (Exhibit 4.1) for specific adjustment provisions and covenants.
- Confirm the dilution impact of the 578,643 new shares and potential future issuance upon warrant exercise.
- Monitor progress of the THIO-101 trial in NSCLC as the designated use of proceeds.